JAVELIN Bladder Medley posts results; avelumab combos tested as maintenance therapy
EMD Serono's Phase II bladder cancer study reports results after evaluating avelumab combinations following first-line chemotherapy.
This week's update centers on a single sponsor record showing new results for a multi-arm avelumab maintenance study.
- "JAVELIN Bladder Medley" (NCT05327530), a Phase II study of avelumab combinations as maintenance therapy in locally advanced or metastatic urothelial carcinoma, is now listed as active not recruiting with results first posted on 2026-09-01.1 The study enrolled 256 participants (actual)1 and reached primary completion on 2025-06-20 (actual).1
- The trial compares avelumab alone against combinations with sacituzumab govitecan, M6223 (an anti-TIGIT antibody), and NKTR-255 (an IL-15 agonist), with Merck KGaA, Darmstadt, Germany, Gilead Sciences, and Nektar Therapeutics listed as collaborators.1
- The primary outcome measure is progression-free survival per RECIST version 1.1 comparing avelumab plus sacituzumab govitecan against avelumab monotherapy, using both the current study's control arm and an external control drawn from the JAVELIN Bladder 100 study.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.